uniQure Shares Surge 26% on Major Analyst Upgrades and Bullish Price Targets

Key Facts

1RBC Capital upgraded uniQure to Outperform, raising the price target from $11 to $35.

2Wells Fargo set an ambitious price target of $60 for the stock with an Overweight rating.

3The departure of Vinay Prasad from the FDA is viewed as a positive factor that could ease the regulatory path for Huntington's disease treatment.

Shares of uniQure (NASDAQ:QURE) surged over 26% following a wave of optimistic analyst upgrades and significantly higher price targets. RBC Capital upgraded the stock to "Outperform," raising its price target from $11 to $35, citing strong potential in the company's pipeline. Wells Fargo set an even more ambitious price target of $60, maintaining an "Overweight" rating on the gene therapy specialist. Market sentiment was further bolstered by the departure of a key official from the FDA, which is expected to ease the regulatory path for its Huntington's disease treatment. The company's progress in gene therapy development remains a primary driver for the recent institutional confidence. These combined factors indicate a robust outlook for uniQure as it navigates critical clinical and regulatory milestones.